Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
An Open-label, Phase Ib Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Sponsor: Infinity Pharmaceuticals, Inc.
Listed as NCT01871675, this PHASE1 trial focuses on Chronic Lymphocytic Leukemia and Lymphoma and remains completed. Sponsored by Infinity Pharmaceuticals, Inc., it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Infinity Pharmaceuticals, Inc.
- SCRI Development Innovations, LLC
For direct contact, visit the study record on ClinicalTrials.gov .